Impact of PET on therapy planning radiation in lung cancer

被引:11
作者
Mac Manus, Michael P.
Hicks, Rodney J.
机构
[1] Peter MacCallum Canc Ctr, Dept Radiat Oncol, Melbourne, Vic 3002, Australia
[2] Peter MacCallum Canc Ctr, Ctr Mol Imaging, Melbourne, Vic 3002, Australia
关键词
D O I
10.1016/j.rcl.2007.05.002
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
The superiority of PET imaging to structural imaging in many cancers is rapidly transforming the practice of radiotherapy planning, especially in lung cancer. Although most lung cancers are potentially treatable with radiation therapy, only patients who have truly locoregionally confined disease can be cured by this modality. PET improves selection for high-dose radiation therapy by excluding many patients who have incurable distant metastasis or extensive locoregional spread. In those patients suitable for definitive treatment, PET can help shape the treatment fields to avoid geographic miss and minimize unnecessary irradiation of normal tissues. PET will allow for more accurately targeted dose escalation studies in the future and could potentially lead to better long-term survival.
引用
收藏
页码:627 / +
页数:13
相关论文
共 71 条
[61]   Randomised multicentre trials of CHART vs conventional radiotherapy in head and neck and non-small-cell lung cancer: An interim report [J].
Saunders, MI ;
Dische, S ;
Barrett, A ;
Parmar, MKB ;
Harvey, A ;
Gibson, D .
BRITISH JOURNAL OF CANCER, 1996, 73 (12) :1455-1462
[62]   Observer variation in target volume delineation of lung cancer related to radiation oncotogist-computer interaction: A 'Big Brother' evaluation [J].
Steenbakkers, RJHM ;
Duppen, JC ;
Fitton, I ;
Deurloo, KEI ;
Zijp, L ;
Uitterhoeve, ALJ ;
Rodrigus, PTR ;
Kramer, GWP ;
Bussink, J ;
De Jaeger, K ;
Belderbos, JSA ;
Hart, AAM ;
Nowak, PJCM ;
van Herk, M ;
Rasch, CRN .
RADIOTHERAPY AND ONCOLOGY, 2005, 77 (02) :182-190
[63]   Developments in radiotherapy [J].
Svensson, H ;
Möller, TR .
ACTA ONCOLOGICA, 2003, 42 (5-6) :430-442
[64]   Positron emission tomography in the management of non-small cell lung cancer [J].
Vansteenkiste, JF ;
Stroobants, SG .
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (01) :269-+
[65]   The impact of 18F-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) lymph node staging on the radiation treatment volumes in patients with non-small cell lung cancer [J].
Vanuytsel, LJ ;
Vansteenkiste, JF ;
Stroobants, SG ;
De Leyn, PR ;
De Wever, W ;
Verbeken, EK ;
Gatti, GG ;
Huyskens, DP ;
Kutcher, GJ .
RADIOTHERAPY AND ONCOLOGY, 2000, 55 (03) :317-324
[66]  
Vesselle H, 2002, CLIN CANCER RES, V8, P3315
[67]   Fluorodeoxyglucose positron emission tomography for melanoma staging: Refining the indications [J].
Wagner, JD .
ANNALS OF SURGICAL ONCOLOGY, 2006, 13 (04) :444-446
[68]   CT AND MR IMAGING IN STAGING NON-SMALL-CELL BRONCHOGENIC-CARCINOMA - REPORT OF THE RADIOLOGIC-DIAGNOSTIC-ONCOLOGY-GROUP [J].
WEBB, WR ;
GATSONIS, C ;
ZERHOUNI, EA ;
HEELAN, RT ;
GLAZER, GM ;
FRANCIS, IR ;
MCNEIL, BJ .
RADIOLOGY, 1991, 178 (03) :705-713
[69]   Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma [J].
Wirth, A ;
Seymour, JF ;
Hicks, RJ ;
Ware, R ;
Fisher, R ;
Prince, M ;
MacManus, MP ;
Ryan, G ;
Januszewicz, H ;
Wolf, M .
AMERICAN JOURNAL OF MEDICINE, 2002, 112 (04) :262-268
[70]   Evaluation of thoracic tumors with 18F-fluorothymidine and 18F-fluorodeoxyglucose-positron emission tomography [J].
Yap, CS ;
Czernin, J ;
Fishbein, MC ;
Cameron, RB ;
Schiepers, C ;
Phelps, ME ;
Weber, WA .
CHEST, 2006, 129 (02) :393-401